Mesoblast (ASX:MSB) Valuation After Earnings Update And New Ryoncil Revenue Guidance

Simply Wall St.

03/03

AdvertisementWhy Mesoblast’s latest guidance matters for shareholders Mesoblast (ASX:MSB) has just paired a detailed half year earnings update with new revenue guidance for its key product Ryoncil, ...

网页链接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2616313728"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2616313728\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2616313728?lang=zh_TW&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-03-03 12:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616313728","market":"us","top_or_hot":-1,"title":"Mesoblast (ASX:MSB) Valuation After Earnings Update And New Ryoncil Revenue Guidance","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy Mesoblast’s latest guidance matters for shareholders Mesoblast (ASX:MSB) has just paired a detailed half year earnings update with new revenue guidance for its key product Ryoncil, ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-after-earnings-update-and-new-ryo\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mesoblast (ASX:MSB) Valuation After Earnings Update And New Ryoncil Revenue Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMesoblast (ASX:MSB) Valuation After Earnings Update And New Ryoncil Revenue Guidance\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Simply Wall St.</strong><span class=\"h-time small\">2026-03-03 12:50</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>AdvertisementWhy Mesoblast’s latest guidance matters for shareholders Mesoblast (ASX:MSB) has just paired a detailed half year earnings update with new revenue guidance for its key product Ryoncil, ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-after-earnings-update-and-new-ryo\">网页链接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-after-earnings-update-and-new-ryo\">Simply Wall St.</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MSB","symbol_name":"美莎比信託","start_time":0,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-after-earnings-update-and-new-ryo","article_id":"2616313728","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-after-earnings-update-and-new-ryo","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2616313728","pubTimestamp":1772513408,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why Mesoblast’s latest guidance matters for shareholders\nMesoblast (ASX:MSB) has just paired a detailed half year earnings update with new revenue guidance for its key product Ryoncil, giving investors fresh numbers on both recent performance and management expectations.\nThe company reported half year revenue of US$51.34 million and a net loss of US$40.16 million, and now forecasts full year 2026 Ryoncil net revenue between US$110 million and US$120 million.\nSee our latest analysis for...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MSB":"美莎比信托","MSB.AU":"MESOBLAST LTD"},"translate_title":"Mesoblast(ASX：MSB)盈利更新和新Ryoncil收入指引后的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MSB.AU":1.5,"MSB":1.5},"content_text":"AdvertisementWhy Mesoblast’s latest guidance matters for shareholders Mesoblast (ASX:MSB) has just paired a detailed half year earnings update with new revenue guidance for its key product Ryoncil, giving investors fresh numbers on both recent performance and management expectations. The company reported half year revenue of US$51.34 million and a net loss of US$40.16 million, and now forecasts full year 2026 Ryoncil net revenue between US$110 million and US$120 million. See our latest analysis for Mesoblast. Despite the fresh Ryoncil guidance and sharp increase in reported half year revenue, Mesoblast’s recent share price performance has been weak. The 30 day share price return shows an 18.18% decline and the year to date share price return shows a 25.27% decline. Over three years, the total shareholder return is around 2.4x, while the one year total shareholder return shows a 17.53% decline, suggesting long term holders have seen sizable gains but more recent momentum has faded. If Mesoblast’s volatility has you reassessing where you look for ideas, this could be a good moment to scan our list of 10 healthcare AI stocks as another way to research market opportunities. With Mesoblast shares showing weak recent returns, despite new Ryoncil revenue guidance and a price that sits well below some analyst targets, you have to ask: is this a mispriced growth story, or is the market already looking ahead? Most Popular Narrative: 46% Undervalued Mesoblast’s most followed valuation narrative puts fair value at A$3.83 per share, compared with the last close of A$2.07, so the gap between price and expectations is wide.  The first and only FDA approved mesenchymal stromal cell product in the U.S., Ryoncil, together with over 1,100 patents and established commercial scale manufacturing, positions Mesoblast to benefit if cell therapies gain wider medical adoption. This would be most visible in revenue growth and operating leverage.  Read the complete narrative. Want to know what kind of revenue ramp and margin shift sits behind that fair value, and how long it is assumed to take? The narrative leans on aggressive top line expansion, a sharp swing in profitability and a valuation multiple usually linked with mature growth leaders. Curious which numbers have to line up for A$3.83 to make sense? Result: Fair Value of A$3.83 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this depends on key risks, including slower than expected Ryoncil uptake relative to the current cash burn and potential delays or setbacks in the planned label expansions. Find out about the key risks to this Mesoblast narrative. Another View: High P/S Ratio Raises Questions The first valuation leans on fast revenue growth and future profitability, but today Mesoblast trades on a P/S ratio of 28.9x, which is well above the Australian Biotechs average of 17.1x, peers at 17.6x, and a fair ratio of 4.8x. If growth or margins slip, how much room is there for disappointment? See what the numbers say about this price — find out in our valuation breakdown. ASX:MSB P/S Ratio as at Mar 2026Next Steps If this mix of potential and concern feels familiar, it may be a good time to review the data yourself and decide where you stand. Our breakdown of 3 key rewards and 1 important warning sign can help you weigh both sides before you act. Looking for more investment ideas? If Mesoblast has sharpened your focus on where you put your capital next, do not stop here. Use the Simply Wall St screener to line up your next watchlist candidates.  Target potential value opportunities by reviewing our 6 high quality undervalued stocks that pair quality fundamentals with prices that differ from underlying estimates. Strengthen your income shortlist by checking out the 6 dividend fortresses that focus on higher yields with an eye on stability. Prioritise resilience first by scanning the 7 resilient stocks with low risk scores identified by our risk scoring, so you are not the last to spot sturdier names.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}